Clinical Trials Directory

Trials / Unknown

UnknownNCT00142324

CALM-AD

A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
190 (planned)
Sponsor
Institute of Psychiatry, London · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Accepted

Summary

Primary Aim To determine whether; * Donepezil is significantly better than placebo in the management of agitation in Alzheimer's Disease that has not responded to, or is inappropriate for a standardised brief psychosocial treatment Secondary Aims To determine whether; * Donepezil has a significant positive or negative impact upon quality of life compared with placebo * whether there is a significant difference between Donepezil and placebo with respect to cognitive performance * the cost effectiveness of the pharmacological treatment for agitation

Conditions

Interventions

TypeNameDescription
DRUGDonepezil

Timeline

Start date
2003-11-01
Completion
2005-12-01
First posted
2005-09-02
Last updated
2005-12-14

Locations

8 sites across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT00142324. Inclusion in this directory is not an endorsement.